Institut pasteur de Dakar
Accueil | News | Actualite de Linstitut | Joint press release between Institut Pasteur Dakar and Satiodx
×

Error message

  • Unable to create CTools CSS cache directory. Check the permissions on your files directory.
  • Unable to create CTools CSS cache directory. Check the permissions on your files directory.

Joint press release between Institut Pasteur Dakar and Satiodx

Satio and the Institut Pasteur de Dakar are forming a strategic partnership on the research, development, manufacturing and distribution of next-generation health technologies.

The partnership aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.


Satio, Inc, a privately held medical device company developing revolutionary consumer-focused diagnostic and drug delivery solutions, today announced a strategic partnership agreement with Institut Pasteur de Dakar.

By combining SatioRx TM intradermal patches and Institut Pasteur de Dakar technologies, the partnership aims to accelerate clinical development and access to vaccine patches for disease outbreaks, as well as diagnostic patches for blood sampling, genetic testing and pathogen surveillance.

The two entities are also collaborating with INTACT, an innovative aseptic packaging company. The collaboration will enable access to immunization by exploring alternatives to vials such as plastic vaccine packets and replacing traditional needles with SatioRxTM intradermal patches and INTACT's aseptic fluid transfer technology. The tripartite collaboration will focus on epidemics with pandemic potential.

Namal Nawana, Chairman and Founder of Satio, said "Satio's technologies are designed to transform healthcare workflows for blood sampling, diagnostics and transdermal drug delivery using our patch-based technology. It is an honor to partner with the Pasteur Institute of Dakar on its important initiatives, specifically for Africa."

"The global COVID pandemic has further highlighted the need for rapid and broad access to vaccines and diagnostics in Africa and beyond. Satio's technology has the potential to radically simplify healthcare workflows and enable delivery at a significantly lower total cost in healthcare systems around the world," said Sharad Joshi, President and CEO of Satio.

Dr. Amadou Alpha Sall, General Administrator of the Institut Pasteur de Dakar Foundation, said, "Access to innovative health technologies for epidemics is essential to ensure an effective response to global threats. This collaboration aims to place Africa at the heart of vaccine innovation."


About Satio, Inc.

Satio, Inc. is a privately held medical device company specializing in point-of-care patches with embedded diagnostic and therapeutic solutions leveraging low-cost, user-friendly technology. The company is developing three different platforms. The first is a vaccine and drug delivery patch that allows for intradermal delivery. The second is a dried blood spot and whole blood collection patches that allow for a wide variety of laboratory and genomic tests. The third is the consumer-based diagnostic patch.

About the Pasteur Institute of Dakar

The Institut Pasteur de Dakar (IPD) is a non-profit public benefit foundation based in Senegal whose mission is to advance public health in Senegal and Africa by conducting research, providing training and education, sharing scientific knowledge and advancing vaccine production. Since its founding in 1896, IPD has been at the forefront of the fight against infectious diseases in West Africa.  It is one of only four manufacturers worldwide to be prequalified by WHO for yellow fever vaccine.

Partenariat IPD et SATIO INC